OmniAb (OABI) Jefferies Global Healthcare Conference summary

Business overview and industry trends

• Operates a licensing model providing innovative antibody discovery technologies to the pharmaceutical industry, addressing critical challenges in drug discovery.

• Antibody-based medicines have higher clinical success rates, driving industry shift from small molecules to antibodies.

• Growth in antibody discovery is fueled by regulatory changes and increased industry understanding of biology and targets.

• Technology is highly scalable, with a growing roster of partners and programs leveraging the platform.

• Mission centers on enabling rapid development of therapeutics by advancing drug discovery technologies.

Technology platform and innovation

• Offers the only four-species transgenic animal platform (rats, mice, chickens, cows) for novel antibody repertoires.

• Launched OmniDab, a chicken-based platform producing single-domain antibodies, expanding applications in CNS and other diseases.

• AI and machine learning are integrated throughout the technology stack, including the OmniDeep suite of in silico tools.

• Screening platforms (xPloration and GEM) enable rapid, efficient screening of millions of B cells, overcoming industry bottlenecks.

• Technologies facilitate discovery against difficult targets and support alternate administration routes for antibodies.

Partnerships, pipeline, and growth

• Ended Q1 with 80 active partners, nearly doubling since 2018, and added three new agreements in the first quarter.

• Currently, 327 programs are progressing through various development stages using the technology.

• Over 30 clinical or approved programs have leveraged the platform, with 4–6 new programs expected to enter the clinic this year.

• Partnerships span large pharma and successful startups, with partners expanding pipelines and raising funds around discovered programs.

• Growth in patent filings by partners extends royalty duration and diversifies the intellectual property pool.